Refined tools for the treatment of hepatocellular carcinoma

Journal of Hepatology

Volumn 42, Issue 5, 2005, Pages 629-631

  Sangro, Bruno ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; DOXORUBICIN; DRUG CARRIER; FLUOROURACIL; GANCICLOVIR; GEMCITABINE; INTERLEUKIN 2; LIPOSOME; OXALIPLATIN; THYMIDINE KINASE; VIRUS VECTOR;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CARDIOMYOPATHY; CLINICAL TRIAL; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TOLERABILITY; DRUG UPTAKE; EDITORIAL; ENCAPSULATION; EXTRACELLULAR MATRIX; FATIGUE; GENE TARGETING; GENE THERAPY; HAIR LOSS; HUMAN; IMMUNE RESPONSE; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; VOMITING;

EID: 17044431355     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2005.02.006     Document Type: Editorial

References (12)

1. L.B. Seeff Introduction: the burden of hepatocellular carcinoma Gastroenterology 127 2004 S1 S4
2. J.M. Llovet, and J. Bruix Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival Hepatology 37 2003 429 442
3. H.J. Broxterman, J. Lankelma, and K. Hoekman Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences Drug Resist Updat 6 2003 111 127
4. L. Barraud, P. Merle, E. Soma, L. Lefrançois, S. Guerret, and M. Chevallier Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo J Hepatol 42 2005 736 743
5. J.W. Valle, A. Dangoor, J. Beech, D.J. Sherlock, S.M. Lee, and J.H. Scarffe Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study Br J Cancer 2005
6. U. Halm, G. Etzrodt, I. Schiefke, F. Schmidt, H. Witzigmann, and J. Mossner A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma Ann Oncol 11 2000 113 114
7. J. Kattan, J.P. Droz, P. Couvreur, J.P. Marino, A. Boutan-Laroze, and P. Rougier Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles Invest New Drugs 10 1992 191 199
8. A.-L. Stefani, L. Barzon, I. Castagliuolo, M. Guido, M. Pacenti, and C. Parolin Systemic efficacy of combined suicide/cytokine gene therapy in a murine model of hepatocellular carcinoma J Hepatol 42 2005 728 735
9. C. Fillat, M. Carrio, A. Cascante, and B. Sangro Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application Curr Gene Ther 3 2003 13 26
10. M. Drozdzik, C. Qian, X. Xie, D. Peng, R. Bilbao, and G. Mazzolini Combined gene therapy with suicide gene and interleukin-12 is more efficient than therapy with one gene alone in a murine model of hepatocellular carcinoma J Hepatol 32 2000 279 286
11. B. Sangro, G. Mazzolini, J. Ruiz, M. Herraiz, J. Quiroga, and I. Herrero Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors J Clin Oncol 22 2004 1389 1397
12. T. Nakajima, M. Moriguchi, Y. Mitsumoto, T. Katagishi, H. Kimura, and H. Shintani Simple tumor profile chart based on cell kinetic parameters and histologic grade is useful for estimating the natural growth rate of hepatocellular carcinoma Hum Pathol 33 2002 92 99